Cytek Biosciences, Inc. CTKB Foreign currency translation gains (losses)
Foreign currency translation gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s foreign currency translation gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s foreign currency translation gains (losses)?
- Cytek Biosciences, Inc. (CTKB) reported foreign currency translation gains (losses) of $328K in Q1 2026.
- How has Cytek Biosciences, Inc.'s foreign currency translation gains (losses) changed year-over-year?
- Cytek Biosciences, Inc.'s foreign currency translation gains (losses) increased by 158.6% year-over-year, from -$560K to $328K.
- What is the long-term trend for Cytek Biosciences, Inc.'s foreign currency translation gains (losses)?
- Over 3 years (2021 to 2025), Cytek Biosciences, Inc.'s foreign currency translation gains (losses) has grown at a 37.6% compound annual growth rate (CAGR), from $832K to $2.17M.
- What does foreign currency translation gains (losses) mean?
- This metric represents the net gains or losses resulting from the translation of financial statements of foreign subsidiaries from their functional currency into the reporting currency. It reflects the impact of exchange rate fluctuations on the value of international assets and liabilities. Monitoring this helps investors understand the company's exposure to currency volatility and the effectiveness of its international operations.